Back to Search
Start Over
Cyclooxygenase inhibition prior to ventricular fibrillation induced ischemia reperfusion injury impairs survival and outcomes.
- Source :
-
Medical hypotheses [Med Hypotheses] 2020 Feb; Vol. 135, pp. 109485. Date of Electronic Publication: 2019 Nov 11. - Publication Year :
- 2020
-
Abstract
- Nonsteroidal anti-inflammatory medications (NSAIDs) are one of the most commonly used analgesics in the world. NSAIDs decrease prostaglandin synthesis through cyclooxygenase inhibition (COX-1 or COX-2). The effects of NSAIDs on survival and outcomes from global ischemia reperfusion events and specifically from cardiac arrest (CA) remain controversial. We hypothesized that NSAIDs prior to global whole-body ischemia reperfusion (I/R) injury impairs survival and outcomes. We explored this hypothesis in our swine model of Cardiac Arrest (CA) which involves global I/R with pretreatment using a predominantly COX-1 inhibitor (Indomethacin [COX-1/min COX-2 Inh], a COX-2 Inhibitor [COX-2-Inh, (Celecoxib)] or placebo control. We determined the effects of each inhibitor on a) survival, b) myocardial injury biomarker (Troponin 1), and c) Autonomic Nervous System (ANS) injury marker (heart rate variability [HRV]) up to 3 h after resuscitation. There were no survivals in COX-1/min COX-2-Inh pretreated animals and, 87% survived in both COX-2 Inhibited and control animals. COX-2 Inh pretreated animals had an 1800 fold increase of Troponin 1 compared to baseline whereas control animals had a 90 fold increase (p < 0.001). These results along with literature review of focal I/R in animal models with COX-2 overexpression, human studies of CA, and post myocardial infarction treatment with NSAIDs, support the hypothesis that NSAIDs prior to an I/R event impairs survival and outcomes. Specifically, predominantly COX-1 inhibition impairs survival, and COX-2 inhibition induces myocardial damage, autonomic nervous system dysfunction, and increases the risk for all-cause mortality and morbidity in humans post-MI which has significant implications for the nearly 10% of the population who are taking NSAIDs.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Subjects :
- Animals
Anti-Inflammatory Agents, Non-Steroidal therapeutic use
Autonomic Nervous System drug effects
Cyclooxygenase 1 metabolism
Cyclooxygenase 2 metabolism
Disease Models, Animal
Heart Arrest drug therapy
Heart Arrest prevention & control
Heart Rate drug effects
Humans
Male
Mice
Registries
Swine
Treatment Outcome
Troponin I metabolism
Ventricular Fibrillation physiopathology
Cyclooxygenase Inhibitors pharmacology
Reperfusion Injury physiopathology
Ventricular Fibrillation drug therapy
Ventricular Fibrillation mortality
Subjects
Details
- Language :
- English
- ISSN :
- 1532-2777
- Volume :
- 135
- Database :
- MEDLINE
- Journal :
- Medical hypotheses
- Publication Type :
- Academic Journal
- Accession number :
- 31734378
- Full Text :
- https://doi.org/10.1016/j.mehy.2019.109485